

Yair Herishanu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6158783/yair-herishanu-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

1,602
citations

17
h-index

38
g-index

106
ext. papers

2,398
ext. citations

4.5
avg, IF

4.81
L-index

#	Paper	IF	Citations
98	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021 , 137, 3165-3173	2.2	274
97	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1278-1291	4.0	201
96	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020 , 34, 2354-2363	10.7	118
95	Leukocytosis in obese individuals: possible link in patients with unexplained persistent neutrophilia. <i>European Journal of Haematology</i> , 2006 , 76, 516-20	3.8	101
94	Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. <i>European Journal of Haematology</i> , 2007 , 79, 205-9	3.8	97
93	Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 173-206	3.1	73
92	CD74 is a novel transcription regulator. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 562-567	11.5	58
91	Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs. <i>Journal of the American Chemical Society</i> , 2020 , 142, 11734-11742	16.4	58
90	Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1407-11	1.9	50
89	Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, 874-882	6.6	43
88	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019 , 62, 1140-1147	5.2	38
87	Fatal interstitial pneumonitis related to rituximab-containing regimen. <i>Clinical Lymphoma and Myeloma</i> , 2006 , 6, 407-9		32
86	Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 195, 186-193	4.5	28
85	Severe hepatitis B virus reactivation related to ibrutinib monotherapy. <i>Annals of Hematology</i> , 2017 , 96, 689-690	3	25
84	Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group. <i>European Journal of Haematology</i> , 2014 , 93, 29-33	3.8	19
83	Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2007 , 79, 150-4	3.8	19
82	Absolute monocyte count trichotomizes chronic lymphocytic leukemia into high risk patients with immune dysregulation, disease progression and poor survival. <i>Leukemia Research</i> , 2013 , 37, 1222-8	2.7	18

81	Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic options. <i>Transfusion and Apheresis Science</i> , 2005 , 32, 85-97	2.4	16
80	Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 3540-3549	8.8	16
79	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016 , 60, 154-65	7.5	16
78	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.. <i>Leukemia</i> , 2022 ,	10.7	15
77	Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e95-9	2	14
76	Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. <i>Haematologica</i> , 2015 , 100, 662-9	6.6	14
75	Efficacy of a Third BNT162b2 mRNA COVID-19 Vaccine Dose in Patients with CLL who Failed Standard Two-dose Vaccination. <i>Blood</i> , 2021 ,	2.2	14
74	Reduced-dose ICE chemotherapy + rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1633-9	1.9	11
73	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021 , 35, 3444-3454	10.7	11
72	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021 , 35, 235-238	10.7	11
71	The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. <i>Anti-Cancer Drugs</i> , 2002 , 13, 177-9	2.4	10
70	Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia. <i>Annals of Medicine</i> , 2017 , 49, 75-82	1.5	9
69	Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel. <i>Anticancer Research</i> , 2018 , 38, 6423-6429	2.3	9
68	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018 , 32, 1869-1873	10.7	8
67	A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach. <i>British Journal of Haematology</i> , 2018 , 182, 125-128	4.5	8
66	Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity. <i>Leukemia Research</i> , 2018 , 71, 1-5	2.7	8
65	Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. <i>Leukemia and Lymphoma</i> , 2021 , 62, 118-124	1.9	8
64	Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulation. <i>Experimental Hematology</i> , 2018 , 63, 17-21.e1	3.1	8

63	Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrations. <i>Leukemia Research</i> , 2014 , 38, 484-9	2.7	7
62	Divergence in CD19-mediated signaling unfolds intraclonal diversity in chronic lymphocytic leukemia, which correlates with disease progression. <i>Journal of Immunology</i> , 2013 , 190, 784-93	5.3	7
61	Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience. <i>Hematological Oncology</i> , 2019 , 37, 185-192	1.3	7
60	Frontline treatment with the combination obinutuzumab + chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020 , 95, 604-611	7.1	6
59	Autoimmune thrombocytopenia in chronic myeloid leukemia treated with interferon-alpha: differential diagnosis and possible pathogenesis. <i>Leukemia and Lymphoma</i> , 2003 , 44, 2103-8	1.9	6
58	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021 , 35, 3059-3072	10.7	6
57	Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival. <i>Hematological Oncology</i> , 2018 , 36, 128-135	1.3	5
56	Measurement of lymphocyte aggregation by flow cytometry-physiological implications in chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2016 , 90, 257-66	3.4	5
55	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018 , 101, 703	3.8	5
54	Complete spontaneous regression of chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, e254-6	2.2	5
53	Fluorine-18 Fluorodeoxyglucose PET/CT Patterns of Extranodal Involvement in Patients with Non-Hodgkin Lymphoma and Hodgkin's Disease. <i>PET Clinics</i> , 2006 , 1, 251-63	2.2	5
52	Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol. <i>Annals of Hematology</i> , 2016 , 95, 1811-8	3	5
51	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021 , 96, E168-E171	7.1	5
50	Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. <i>European Journal of Haematology</i> , 2018 , 101, 399-406	3.8	5
49	A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain. <i>European Journal of Haematology</i> , 2019 , 103, 335-341	3.8	4
48	BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.. <i>British Journal of Haematology</i> , 2022 ,	4.5	4
47	Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. <i>Journal of Medical Virology</i> , 2021 ,	19.7	4
46	The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants. <i>British Journal of Haematology</i> , 2020 , 189, e31-e33	4.5	3

45	Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1163-1171	1.9	3
44	B-cell receptor signaling in chronic lymphocytic leukemia leans on Lyn. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1125-6	1.9	3
43	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021 , 96, E306-E310	7.1	3
42	Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1136-1145	1.9	3
41	Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2021 , 192, e1-e4	4.5	3
40	Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients - a matched control multi-center cohort study. <i>Haematologica</i> , 2021 ,	6.6	3
39	COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now. <i>Cancer Journal (Sudbury, Mass)</i> , 2021 , 27, 328-333	2.2	3
38	JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts. <i>Israel Medical Association Journal</i> , 2013 , 15, 698-700	0.9	3
37	Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study. <i>American Journal of Hematology</i> , 2019 , 94, 992-1001	7.1	2
36	Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2012 , 89, 430-1	3.8	2
35	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020 , 136, 45-49	2.2	2
34	Correlation Between BNT162b2 mRNA Covid-19 Vaccine-associated Hypermetabolic Lymphadenopathy and Humoral Immunity in Patients With Hematologic Malignancy		2
33	Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells. <i>Frontiers in Oncology</i> , 2021 , 11, 646971	5.3	2
32	Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells. <i>European Journal of Haematology</i> , 2022 , 108, 52-60	3.8	2
31	Fragility of sub-cellular structures in chronic lymphocytic leukemia. <i>International Journal of Hematology</i> , 2017 , 105, 707-708	2.3	1
30	Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia. <i>Leukemia Research</i> , 2019 , 82, 24-28	2.7	1
29	Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study. <i>Annals of Hematology</i> , 2018 , 97, 459-466	3	1
28	Cancer Registries Often Underestimate the True Incidence of CLL. <i>Blood</i> , 2014 , 124, 5646-5646	2.2	1

27	Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience. <i>Blood</i> , 2014 , 124, 5659-5659	2.2	1
26	Rituximab Retreatment in B-Cell Non-Hodgkins Lymphoma Patients.. <i>Blood</i> , 2005 , 106, 2455-2455	2.2	1
25	Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner. <i>Oncogene</i> , 2020 , 39, 1997-2008	9.2	1
24	Feasibility of CD24/CD11b as a Screening Test for Hematological Malignancies. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
23	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021 , 106, 493-499	3.8	1
22	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.. <i>Annals of Hematology</i> , 2022 , 101, 755	3	0
21	Prognostic Significance of the FISH Panel for Patients with Multiple Myeloma. <i>Blood</i> , 2012 , 120, 5001-5001	2.2	0
20	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021 , 138, 2635-2635	2.2	0
19	Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19. <i>Patient Preference and Adherence</i> , 2021 , 15, 945-952	2.4	0
18	Wide-range effects of the MALT-1 inhibitor Mi-2 in CLL cells results in apoptosis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 817-820	1.9	0
17	CT findings are highly predictive for perforation in patients with diffuse large B-cell lymphoma involving the intestines. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1878-1883	1.9	0
16	COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge.. <i>Cancer Cell</i> , 2022 ,	24.3	0
15	Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews. <i>European Journal of Haematology</i> , 2017 , 99, 51-55	3.8	
14	Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study. <i>Blood</i> , 2021 , 138, 3727-3727	2.2	
13	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. <i>Blood</i> , 2021 , 138, 2641-2641	2.2	
12	The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective. <i>Blood</i> , 2021 , 138, 4686-4686	2.2	
11	Quantitation of Zap-70 Expression in B-CLL Cells Employing a Novel Flow Cytometry Analysis Method.. <i>Blood</i> , 2004 , 104, 4785-4785	2.2	
10	Detection of ZAP70 Negative B-CLL Patients Using the Beckman Coulters Positional Parameter Technology and RPD (Research Population Data) Analysis.. <i>Blood</i> , 2006 , 108, 4934-4934	2.2	

- 9 Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.. *Journal of Clinical Oncology*, **2020**, 38, e20011-e20011 2.2
- 8 High Peripheral Blood Circulating BDNF Levels Are Associated with Good Prognosis in CLL Patients; A CXCR-4 Dependent Effect?. *Blood*, **2016**, 128, 5562-5562 2.2
- 7 Intra-Clonal Diversity Identified by CD19-Mediated Signaling Correlates with Disease Progression In Chronic Lymphocytic Leukemia (CLL). *Blood*, **2010**, 116, 3577-3577 2.2
- 6 Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.. *Blood*, **2010**, 116, 4620-4620 2.2
- 5 Increased CD39 Expression on CD4+ T-Lymphocytes Has Clinical and Prognostic Significance in Chronic Lymphocytic Leukemia,. *Blood*, **2011**, 118, 3895-3895 2.2
- 4 Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,. *Blood*, **2011**, 118, 3811-3811 2.2
- 3 Divergence in CD19-Mediated Signaling Unfolds Intra-Clonal Diversity in Chronic Lymphocytic Leukemia Which Correlates with Disease Progression. *Blood*, **2012**, 120, 4570-4570 2.2
- 2 Richter's Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors. *Blood*, **2013**, 122, 5281-5281 2.2
- 1 Absolute Monocyte Count Trichotomizes Chronic Lymphocytic Leukemia Into High Risk Patients With Immune Dysregulation, Disease Progression and Poor Survival. *Blood*, **2013**, 122, 4724-4724 2.2